[go: up one dir, main page]

CU20160063A7 - Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x - Google Patents

Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x

Info

Publication number
CU20160063A7
CU20160063A7 CUP2016000063A CU20160063A CU20160063A7 CU 20160063 A7 CU20160063 A7 CU 20160063A7 CU P2016000063 A CUP2016000063 A CU P2016000063A CU 20160063 A CU20160063 A CU 20160063A CU 20160063 A7 CU20160063 A7 CU 20160063A7
Authority
CU
Cuba
Prior art keywords
farnesoid
fusioned
active
receptor modulators
pirazol derivatives
Prior art date
Application number
CUP2016000063A
Other languages
English (en)
Other versions
CU24375B1 (es
Inventor
Donatella Chianelli
Xiaodong Liu
Valentina Molteni
John Nelson
Jason Roland
Paul Rucker
David Tully
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160063(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20160063A7 publication Critical patent/CU20160063A7/es
Publication of CU24375B1 publication Critical patent/CU24375B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos derivados de pirazol fusionados de Ia formula I: ESPACIO PARA FÓRMULA un estereoisómero, enantiómero, una sal farmacéuticamente aceptable o un conjugado aminoácido del mismo; en donde las variables son como se definen en el presente documento; y sus composiciones farmacéuticas, que son útiles como moduladores de Ia actividad de los receptores X farnesoides (FXR).
CU2016000063A 2013-11-05 2014-11-04 Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x CU24375B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05
PCT/US2014/063948 WO2015069666A1 (en) 2013-11-05 2014-11-04 Compositions and methods for modulating farnesoid x receptors

Publications (2)

Publication Number Publication Date
CU20160063A7 true CU20160063A7 (es) 2016-09-30
CU24375B1 CU24375B1 (es) 2018-12-05

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000063A CU24375B1 (es) 2013-11-05 2014-11-04 Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x

Country Status (42)

Country Link
US (5) US9682939B2 (es)
EP (1) EP3065738B1 (es)
JP (1) JP6424231B2 (es)
KR (1) KR102350357B1 (es)
CN (1) CN105682656B (es)
AP (1) AP2016009165A0 (es)
AR (1) AR098316A1 (es)
AU (1) AU2014346919B2 (es)
BR (1) BR112016009630B1 (es)
CA (1) CA2927705C (es)
CL (1) CL2016000982A1 (es)
CR (1) CR20160212A (es)
CU (1) CU24375B1 (es)
CY (1) CY1120273T1 (es)
DK (1) DK3065738T3 (es)
EA (1) EA030430B1 (es)
ES (1) ES2670984T3 (es)
GT (1) GT201600085A (es)
HR (1) HRP20180817T1 (es)
HU (1) HUE039155T2 (es)
IL (1) IL245242B (es)
JO (1) JO3454B1 (es)
LT (1) LT3065738T (es)
MA (1) MA39088B1 (es)
MX (1) MX364834B (es)
MY (1) MY175903A (es)
NO (1) NO3105103T3 (es)
NZ (1) NZ719078A (es)
PE (1) PE20160682A1 (es)
PH (1) PH12016500777B1 (es)
PL (1) PL3065738T3 (es)
PT (1) PT3065738T (es)
RS (1) RS57179B1 (es)
SG (1) SG11201603026PA (es)
SI (1) SI3065738T1 (es)
SV (1) SV2016005192A (es)
TN (1) TN2016000143A1 (es)
TR (1) TR201807321T4 (es)
TW (1) TWI662027B (es)
UY (1) UY35818A (es)
WO (1) WO2015069666A1 (es)
ZA (1) ZA201602555B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
HUE039155T2 (hu) 2013-11-05 2018-12-28 Novartis Ag Készítmények és eljárások farnezoid X receptorok modulálására
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
JP6691552B2 (ja) * 2015-04-30 2020-04-28 ノバルティス アーゲー ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体
CA3013186A1 (en) 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
US11052069B2 (en) * 2016-09-14 2021-07-06 Novartis Ag Regimes of FXR agonists
MX2019003889A (es) * 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
BR112019025797A2 (pt) * 2017-06-05 2020-07-07 National University Of Singapore compostos úteis na inibição do fator trefoil 3 humano
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
SG11202001166RA (en) * 2017-08-15 2020-03-30 Inflazome Ltd Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Ｆｘｒアゴニストを含む組合せ
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
AU2018363771A1 (en) 2017-11-09 2020-05-14 Inflazome Limited Novel sulfonamide carboxamide compounds
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
EP4329761A1 (en) 2021-04-28 2024-03-06 ENYO Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024044778A2 (en) * 2022-08-26 2024-02-29 Celmatix Inc. Novel modulators of fshr and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
DK2029547T3 (da) * 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
WO2008033534A2 (en) * 2006-09-15 2008-03-20 Thales Avionics, Inc. System and method for wirelessly transferring content to and from an aircraft
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
HUE039155T2 (hu) 2013-11-05 2018-12-28 Novartis Ag Készítmények és eljárások farnezoid X receptorok modulálására
JP6691552B2 (ja) 2015-04-30 2020-04-28 ノバルティス アーゲー ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体

Also Published As

Publication number Publication date
CR20160212A (es) 2016-07-22
KR102350357B1 (ko) 2022-01-14
TWI662027B (zh) 2019-06-11
IL245242B (en) 2019-03-31
EP3065738B1 (en) 2018-02-28
US9682939B2 (en) 2017-06-20
JP2016535784A (ja) 2016-11-17
US10683271B2 (en) 2020-06-16
MX2016005865A (es) 2016-07-13
US20210253534A1 (en) 2021-08-19
PH12016500777A1 (en) 2016-05-30
US11021446B2 (en) 2021-06-01
CY1120273T1 (el) 2019-07-10
MA39088A1 (fr) 2017-07-31
JP6424231B2 (ja) 2018-11-14
HUE039155T2 (hu) 2018-12-28
BR112016009630B1 (pt) 2021-02-09
TN2016000143A1 (en) 2017-10-06
AU2014346919B2 (en) 2017-02-02
CU24375B1 (es) 2018-12-05
MY175903A (en) 2020-07-15
US20200247757A1 (en) 2020-08-06
PH12016500777B1 (en) 2016-05-30
MX364834B (es) 2019-05-08
AR098316A1 (es) 2016-05-26
GT201600085A (es) 2019-07-19
US10077240B2 (en) 2018-09-18
CN105682656A (zh) 2016-06-15
PT3065738T (pt) 2018-06-04
SI3065738T1 (en) 2018-06-29
PL3065738T3 (pl) 2018-07-31
LT3065738T (lt) 2018-05-10
US20190062283A1 (en) 2019-02-28
ZA201602555B (en) 2017-06-28
US20160340317A1 (en) 2016-11-24
BR112016009630A8 (pt) 2020-04-07
NO3105103T3 (es) 2018-05-12
MA39088B1 (fr) 2018-06-29
PE20160682A1 (es) 2016-07-23
EA201690930A1 (ru) 2016-08-31
CA2927705C (en) 2021-09-21
CA2927705A1 (en) 2015-05-14
ES2670984T3 (es) 2018-06-04
DK3065738T3 (en) 2018-06-06
TR201807321T4 (tr) 2018-06-21
KR20160079091A (ko) 2016-07-05
WO2015069666A1 (en) 2015-05-14
US20170275256A1 (en) 2017-09-28
CN105682656B (zh) 2019-11-05
JO3454B1 (ar) 2020-07-05
UY35818A (es) 2015-05-29
TW201612163A (en) 2016-04-01
SG11201603026PA (en) 2016-05-30
CL2016000982A1 (es) 2016-10-07
IL245242A0 (en) 2016-06-30
SV2016005192A (es) 2016-11-21
AP2016009165A0 (en) 2016-04-30
HRP20180817T1 (hr) 2018-06-29
RS57179B1 (sr) 2018-07-31
EA030430B1 (ru) 2018-08-31
NZ719078A (en) 2018-07-27
EP3065738A1 (en) 2016-09-14
AU2014346919A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
CU20160063A7 (es) Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
UY33815A (es) Composiciones y métodos para modular el fxr
ECSP18030284A (es) Moduladores del receptor x farnesoide
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
NI201300068A (es) Moduladores del receptor de glucagón
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201692037A1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
CU20170037A7 (es) Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c)pirrol moduladores alostéricos negativos de nr2b
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201501163A1 (ru) Модуляторы рецептора cxcr7
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
CU20130159A7 (es) Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina